Janux Therapeutics (JANX) said Tuesday it started an underwritten public offering of $300 million of shares or pre-funded warrants to buy shares.
Underwriters will be given a 30-day option to buy up to an additional $45 million of shares, the company said.
The offering is subject to market conditions, and there's no assurance as to whether or when it may be completed, its actual size or terms, Janux said.
Net proceeds will be used to advance the clinical development of the company's product pipeline and for general corporate purposes, according to the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。